-
-
-
-
-
-
-
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
-
-
-
-
-
-
-
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
-
-
-
-
-
-
-
TG Therapeutics data shows BRIUMVI reduces relapse rates in active MS patients
-
-
-
-
-
-
-
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
-
-
-
-
-
-
-
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
-
-
-
-
-
-
-
TG Therapeutics completes $100 million buyback, authorizes new program
-
1,160,146 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

